Overview

Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal

Status:
Terminated

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

There is increasing evidence of a role of EGFR, treatment with EGFR-inhibitors in anal cancer and synergies of EGFR-inhibitors with radiotherapy. Addition of the human anti-EGFR antibody Panitumumab to chemoradiotherapy seems therefore solidly justified. This trial investigates concurrent panitumumab/capecitabine/mitomycin concurrent to IMRT-radiotherapy. Treatment components used in this study have been selected on scientific rationale. The trial regimen should be feasible with acceptable toxicity and outcome similar to historic series.

Phase:

Phase 2

Details

Lead Sponsor:

Centre Hospitalier Universitaire Vaudois

Treatments:

Antibodies, Monoclonal
Capecitabine
Mitomycin
Mitomycins
Panitumumab